Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05478694 · ClinicalTrials.gov registry record

Outcomes of Focal Ablation for Prostate Cancer

A clinical trial of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
225
Enrollment target
1
Study location

NCT05478694: Recruiting study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.

NCT05478694 is a study of Prostate Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 225 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05478694, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
225 participants
Enrollment target
1
Study location

Study Summary

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Primary Outcome

Oncologic outcomes will be assessed by the rate of negative in-field biopsy at 12 months which is defined by the Delphi consensus criterion of absence of clinically significant disease (≤ 3 mm of Gleason ≤ 6 disease in any biopsy core is insignificant)

Conditions Studied

Prostate Cancer

Study Locations (1)

Texas

  • UTSW - Dallas

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2023-02-01
Est. Completion 2026-08
University of Texas Southwestern Medical Center

837 total trials

What NCT05478694 shows while recruiting

NCT05478694 is an observational study that tracks outcomes without assigning an intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT05478694 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05478694 about?

NCT05478694 is a clinical study titled "Outcomes of Focal Ablation for Prostate Cancer". This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

What is the current status of trial NCT05478694?

This trial is currently recruiting. The enrollment target is 225 participants. The study started on 2023-02-01. Estimated completion is 2026-08.

What conditions does trial NCT05478694 study?

This clinical trial studies the following conditions: Prostate Cancer.

Who is sponsoring clinical trial NCT05478694?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05478694 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05478694's enrollment target sits among peer trials

225 201st of 735 higher than 534 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03955445 · 225 participants · Phase 3

    Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

  • NCT04054310 · 225 participants · NA

    Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

  • NCT04480554 · 225 participants · Phase 2

    Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

  • NCT04888104 · 225 participants

    Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05478694

Source: ClinicalTrials.gov NCT05478694, the US trial registry maintained by the National Library of Medicine. NCT05478694 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.